$MBRX
Moleculin Biotech, Inc.

2016 Q4 Form 10-Q Financial Statement

#000114420416135472 Filed on November 21, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $530.0K $920.0K
YoY Change
% of Gross Profit
Research & Development $880.0K $497.0K
YoY Change 1193.97%
% of Gross Profit
Depreciation & Amortization $10.00K $1.000K
YoY Change
% of Gross Profit
Operating Expenses $1.420M $1.422M
YoY Change 538.38%
Operating Profit -$1.422M
YoY Change 538.38%
Interest Expense -$10.00K $10.00K
YoY Change 540.2%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.420M -$1.430M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$1.420M -$1.432M
YoY Change 538.39%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.868M -$740.9K
COMMON SHARES
Basic Shares Outstanding 12.05M shares 11.25M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.010M $6.180M
YoY Change
Cash & Equivalents $5.007M $6.184M $28.00K
Short-Term Investments
Other Short-Term Assets $220.0K $240.0K
YoY Change
Inventory
Prepaid Expenses $215.0K $244.9K $0.00
Receivables
Other Receivables
Total Short-Term Assets $5.222M $6.429M $28.09K
YoY Change 18489.58%
LONG-TERM ASSETS
Property, Plant & Equipment $23.00K $16.35K $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.17M $11.15M $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $5.222M $6.429M $28.09K
Total Long-Term Assets $11.17M $11.15M $0.00
Total Assets $16.39M $17.57M $28.09K
YoY Change 58256.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $399.0K $980.0K
YoY Change
Accrued Expenses $650.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $300.0K $300.0K
YoY Change
Total Short-Term Liabilities $1.345M $1.280M $772.8K
YoY Change 74.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $50.00K
YoY Change
Other Long-Term Liabilities $90.00K $50.00K $0.00
YoY Change
Total Long-Term Liabilities $90.00K $50.00K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.345M $1.280M $772.8K
Total Long-Term Liabilities $90.00K $50.00K $0.00
Total Liabilities $1.433M $1.330M $772.8K
YoY Change 85.43%
SHAREHOLDERS EQUITY
Retained Earnings -$4.675M -$3.251M -$748.4K
YoY Change 524.7%
Common Stock $19.64M $19.50M $6.661K
YoY Change 294675.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.96M $16.24M -$745.0K
YoY Change
Total Liabilities & Shareholders Equity $16.39M $17.57M $28.09K
YoY Change 58256.77%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q4
OPERATING ACTIVITIES
Net Income -$1.420M -$1.432M
YoY Change 538.39%
Depreciation, Depletion And Amortization $10.00K $1.000K
YoY Change
Cash From Operating Activities -$1.160M -$950.0K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$100.0K
YoY Change
Cash From Investing Activities -$10.00K -$110.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -1.160M -950.0K
Cash From Investing Activities -10.00K -110.0K
Cash From Financing Activities 10.00K 0.000
Net Change In Cash -1.160M -1.060M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$1.160M -$950.0K
Capital Expenditures -$10.00K -$10.00K
Free Cash Flow -$1.150M -$940.0K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Trading Symbol
TradingSymbol
MBRX
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q3 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
3000 USD
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17573788 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28091 USD
CY2016Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
50000 USD
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12054813 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001659617
dei Entity Registrant Name
EntityRegistrantName
Moleculin Biotech, Inc.
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
CY2016Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
37500 USD
CY2015Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
450000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
772790 USD
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
12055 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
6661 USD
CY2016Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
297656 USD
CY2016Q3 us-gaap Liabilities
Liabilities
1330153 USD
CY2015Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
3000 USD
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
19485987 USD
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
0 USD
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3251407 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-748360 USD
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
16243635 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-744699 USD
CY2015Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
63010 USD
CY2016Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
244869 USD
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0 USD
CY2016Q3 us-gaap Assets Current
AssetsCurrent
6428652 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
28091 USD
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16346 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 USD
CY2016Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11128790 USD
CY2015Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
0 USD
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1280153 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
772790 USD
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
322790 USD
CY2016Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
944997 USD
CY2015Q4 us-gaap Assets
Assets
28091 USD
CY2016Q3 us-gaap Assets
Assets
17573788 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28091 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6183783 USD
us-gaap Net Income Loss
NetIncomeLoss
-2503047 USD
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2016Q3 us-gaap Interest Expense
InterestExpense
10402 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-1432079 USD
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11579239 shares
CY2016Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
977 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1629 USD
us-gaap Share Based Compensation
ShareBasedCompensation
208939 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-146799 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2596647 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-109793 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8862132 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6155692 USD
us-gaap Interest Paid
InterestPaid
47950 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
244869 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
9167071 USD
us-gaap Stock Issued1
StockIssued1
9773586 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
341785 USD
CY2015Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0 USD
us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
616498 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1847613 USD
us-gaap Operating Expenses
OperatingExpenses
2465740 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2465740 USD
us-gaap Interest Expense
InterestExpense
37307 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2015Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
23000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1421677 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9066804 shares
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
496659 USD
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
924041 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
1421677 USD
CY2015Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-162660 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
469939 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
165000 USD
mbrx Debt Instrument Convertible Number Of Common Shares
DebtInstrumentConvertibleNumberOfCommonShares
1928899 shares
CY2016Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1166503 shares
CY2016Q2 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
183356 USD
CY2016Q2 us-gaap Interest Payable Current
InterestPayableCurrent
17699 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Expiration Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
2025-12-05
mbrx Operating Loss Carryforwards Expiration Period
OperatingLossCarryforwardsExpirationPeriod
2035
CY2016Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
3343000 USD
CY2016Q2 mbrx Shares Authorized
SharesAuthorized
80000000 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q2 mbrx Class Of Warrant Or Right Period From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable
P5Y
CY2016Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
107802 shares
CY2016Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.50
CY2016Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
1000000 USD
CY2016Q2 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
750000 USD
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Use of Estimates in Financial Statement Presentation -</font></b> <font style="FONT-SIZE: 10pt"> The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
184344 USD
CY2015Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0 USD
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
222753 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-222753 USD
CY2015Q3 us-gaap Interest Expense
InterestExpense
1562 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-224315 USD
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4320015 shares
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
CY2015Q3 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.20
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10155 USD
CY2016Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
5693442 USD
CY2015Q3 us-gaap Stock Issued1
StockIssued1
0 USD
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12054813 shares
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12054813 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6661000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6661000 shares
CY2015Q3 us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38409 USD
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
CY2015Q3 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
250000 USD
CY2015Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
CY2015Q3 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
250000 USD
CY2015Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
87340 USD
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87340 USD
CY2015Q3 us-gaap Interest Paid
InterestPaid
0 USD
CY2015Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2016Q3 us-gaap Interest Payable Current
InterestPayableCurrent
6742 USD
mbrx Debt Conversion Converted Instrument Common Stock Shares Issued Trading Restrictions Description
DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription
(a) beginning 90 days after the initial closing of our IPO and until the one-year anniversary of the initial closing of the IPO, the holder of the note will be able to sell 1% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the note can sell up to 3% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (c) if the common stock price is over $10.00 per share for five consecutive trading days then the holder of the note can sell up to an additional 5% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 7% of the daily volume; and (d) if the common stock price is over $14.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock price falls back below $14.00 per share; and (b) thereafter, until the two-year anniversary of the initial closing of IPO, the holder of the note can sell on any trading day 10% of the daily volume; provided that if the common stock price is over $10.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock falls back below $10.00 per share. The foregoing lock-up restrictions relate to public sales and do not restrict the transfer of the shares privately, if permitted by applicable law, provided the acquirer of the shares agrees to comply with the above restrictions with respect to any public sales.
CY2016Q3 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
800057 shares
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
133988 USD
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
234296 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
702888 USD
CY2015Q3 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
200000 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
510000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.83
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.20
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y8M1D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M14D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
460000 shares
mbrx Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.38
CY2016Q3 mbrx Business Acquisition Pro Forma Weighted Average Number Of Shares Outstanding Basic And Diluted
BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted
11579239 shares
CY2015Q3 mbrx Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
150000 shares
mbrx Common Stock Lockup And Leakout Agreements Description
CommonStockLockupAndLeakoutAgreementsDescription
These shares are subject to the following lock-up agreement, from and after the later of six months after issuance or 90 days from the effective date of our IPO registration statement until the one-year anniversary thereof, (a) the holder of the shares can sell up to 10% of the purchased shares per month, subject to a maximum sale on any trading day of 8% of the daily volume of the common stock; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the shares can sell up to 20% of the purchased shares per month, subject to a maximum sale on any trading day of 10% of the daily volume of the common stock; and (c) if the common stock price is over $12.00 per share then the holder of the shares is not restricted from making any sales until such time as the common stock price falls back below $12.00 per share.
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
50000 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.20
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
87500 USD
CY2015Q3 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
19584 USD
mbrx Shares Subscribed
SharesSubscribed
0 USD
CY2015Q3 mbrx Shares Subscribed
SharesSubscribed
4600 USD
mbrx Shares Issued For Licenses Used For Research And Development
SharesIssuedForLicensesUsedForResearchAndDevelopment
0 USD
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
275500 USD
CY2015Q3 mbrx Shares Issued For Licenses Used For Research And Development
SharesIssuedForLicensesUsedForResearchAndDevelopment
-2061 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
275500 USD
CY2015Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2016Q3 mbrx Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.12
CY2016Q3 mbrx Business Acquistion Pro Forma Operating Expenses
BusinessAcquistionProFormaOperatingExpenses
1421677 USD
mbrx Business Acquistion Pro Forma Operating Expenses
BusinessAcquistionProFormaOperatingExpenses
2561908 USD
CY2015Q3 mbrx Business Acquistion Pro Forma Operating Expenses
BusinessAcquistionProFormaOperatingExpenses
295422 USD
mbrx Business Acquistion Pro Forma Operating Expenses
BusinessAcquistionProFormaOperatingExpenses
769549 USD
CY2016Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-1432079 USD
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-2539677 USD
CY2015Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-297129 USD
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-779779 USD
mbrx Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.27
mbrx Business Acquisition Pro Forma Weighted Average Number Of Shares Outstanding Basic And Diluted
BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted
9513660 shares
CY2015Q3 mbrx Business Acquisition Pro Forma Weighted Average Number Of Shares Outstanding Basic And Diluted
BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted
4052116 shares
mbrx Business Acquisition Pro Forma Weighted Average Number Of Shares Outstanding Basic And Diluted
BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted
2028506 shares
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
99638 USD
CY2015Q3 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD

Files In Submission

Name View Source Status
0001144204-16-135472-index-headers.html Edgar Link pending
0001144204-16-135472-index.html Edgar Link pending
0001144204-16-135472.txt Edgar Link pending
0001144204-16-135472-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mbrx-20160930.xml Edgar Link completed
mbrx-20160930.xsd Edgar Link pending
mbrx-20160930_cal.xml Edgar Link unprocessable
mbrx-20160930_def.xml Edgar Link unprocessable
mbrx-20160930_lab.xml Edgar Link unprocessable
mbrx-20160930_pre.xml Edgar Link unprocessable
pg1img1_10q.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v451792_10q.htm Edgar Link pending
v451792_ex10-4.htm Edgar Link pending
v451792_ex31-1.htm Edgar Link pending
v451792_ex31-2.htm Edgar Link pending
v451792_ex32-1.htm Edgar Link pending
v451792_ex32-2.htm Edgar Link pending